In cancer, tumor suppressor genes (TSGs) are frequently truncated, causing their encoded products to be non-functional or dominant-negative. We previously showed that premature polyadenylation (pPA) of MAGI3 truncates the gene, switching its functional role from a TSG to a dominant-negative oncogene. Here we report that MAGI3 undergoes pPA at the intron immediately downstream of its large internal exon, which is normally highly modified by N 6 -methyladenosine (m 6 A). In breast cancer cells that upregulate MAGI3 pPA , m 6 A levels in the large internal exon of MAGI3 are significantly reduced compared to cells that do not express MAGI3 pPA . We further find that MAGI3 pPA transcripts are significantly depleted of m 6 A modifications, in contrast to highly m 6 A-modified full-length MAGI3 mRNA. Finally, we analyze public expression data and find that other TSGs, including LATS1 and BRCA1, also undergo intronic pPA following large internal exons, and that m 6 A levels in these exons are reduced in pPA-activated breast cancer cells relative to untransformed mammary cells. Our study suggests that m 6 A may play a role in regulating intronic pPA of MAGI3 and possibly other TSGs, warranting further investigation.
SCIenTIfIC REPoRTs | (2018) 8:1415 | DOI:10.1038/s41598-018-19916-8 pre-mRNAs from pPA, results in activation of multiple intronic PAS in the 5′ regions of most genes 3 , with a strong bias for PAS in intron 1 5 . These results cannot account for the focal pPA event occurring in intron 10 of MAGI3
4 , yet not in upstream introns that are more likely to be affected by trans-acting factors. Intrigued by the specific occurrence of pPA following exon 10 of MAGI3 but not following other exons of the gene, we hypothesized that novel cis-acting elements may mark and render this gene region, and possibly others like it, susceptible to focal pPA events.
Results
Intronic pPA of MAGI3 occurs following the gene's large internal exon. To understand the focal nature of pPA in the MAGI3 gene, we first examined the structure of the entire gene. MAGI3 is a large gene comprised of 21 exons (Fig. 1A) . As reported more extensively in our previous work 4 , breast cancer-associated pPA of MAGI3 occurs in intron 10, following exon 10 ( Fig. 1A) . This event leads to the expression of a truncated, dominantly-acting oncogene (Fig. 1B) , which can be detected by both 3′ rapid amplification of cDNA ends (RACE) and immunoblotting in MDA-MB-231 human breast cancer cells but not in MCF10A non-transformed human mammary cells (Fig. 1C and D ) 4 . Upon examining the gene structure, we noticed that the occurence of pPA in intron 10 might be particularly significant since the preceding exon is by far the largest in the gene at 606 nt. The size of exon 10 is additionally noteworthy because large internal exons are a rare class of exons in the genome, likely because efficient splicing favors exon sizes less than 200 nt 6 . Thus, we hypothesized that a molecular mechanism which normally limits the usage of the intronic PAS downstream of the large internal exon of MAGI3 may be deregulated in cancer.
N
6 -methyladenosine (m 6 A) is normally enriched in the large internal exon of MAGI3, but its levels are reduced in pPA-activated MDA-MB-231 cells. To begin to test our hypothesis, we asked whether molecular marks enriched in large internal exons might correlate with the expression of MAGI3 pPA . Interestingly, studies examining methylation of mRNA at N 6 -adenosine (N 6 -methyladenosine or m 6 A) on a transcriptome-wide scale have previously reported consistent enrichment of m 6 A in large internal exons as well as terminal exons across several human cell lines 7, 8 . While the functional significance of these modifications in pPA proteins are detected by immunoblotting. Immunoblot of β-actin is included to show loading, approximate molecular mass markers are indicated in kDa, and the relative levels of full-length and pPA-truncated MAGI3 proteins were normalized to β-actin levels.
SCIenTIfIC REPoRTs | (2018) 8:1415 | DOI:10.1038/s41598-018-19916-8 large internal exons has remained unclear, m 6 A density in terminal exons has been found to correlate inversely with proximal PAS usage in 3′ UTR alternative polyadenylation 9 . These data raise the possibility that m 6 A may influence the usage of proximal downstream PAS.
Interrogating two transcriptome-wide m 6 A sequencing (m 6 A-Seq) datasets generated in the human hepatocellular carcinoma HepG2 and non-malignant human embryonic kidney HEK293T cell lines 7, 8 , we found strong enrichment of m 6 A peaks in the large internal exon of MAGI3 ( Fig. 2A) . Notably, the concordance between the m 6 A peaks found in HepG2 and HEK293T cells was very strong. By normalizing the number of m 6 A reads to exon length, we observed that the vast majority of m 6 A marks in the MAGI3 mRNA are contained in the large internal exon (Fig. 2A) . Previous work has identified the m 6 A consensus sequence RRACU, where R is either G or A 7, 8 . In the 606-nt large internal exon of MAGI3, we found only two RRACU sequences, each positioned at the center of the two observed m 6 A-Seq peaks (Fig. 2B ). To validate m 6 A presence in the MAGI3 large internal exon, we used a m 6 A-specific antibody to perform RNA immunoprecipitation (RIP) on ~100-nt chemically fragmented, poly(A)-purified RNA from MCF10A mammary epithelial cells. Relative methylation levels of fragments containing m 6 A consensus sites in the large internal exon of MAGI3 were determined by real-time PCR (qPCR) using flanking primers. To confirm the specificity of m 6 A RIP-qPCR, we included as negative controls primers flanking exonic regions (exons 1-2) of MAGI3 located far from m 6 A consensus sites (distal mRNA segments). Indeed, after we performed m 6 A RIP-qPCR, immunoprecipitated mRNA fragments containing the m 6 A consensus sites of the MAGI3 large internal exon were detected at high levels, whereas distal mRNA fragments were hardly detected at all (Fig. 2C) .
We next focused on validating that m 6 A modifications at the two identified sites in the large internal exon of MAGI3 functionally promotes interaction with known m 6 A-binding proteins. Thus, we synthesized two biotinylated RNA moieties spanning each site, one m 6 A-modified within the RRACU motif and the other unmodified. Following incubation with MCF10A nuclear lysates, we immunoprecipitated the synthesized RNA by streptavidin-bound beads and performed mass spectrometry analysis (RIP-MS) on the bound samples. This analysis yielded three proteins enriched in the m 6 A-modified RIP samples of each site, including the m 6 A-binding proteins YTHDF1 and YTHDF3 (Table 1) , thereby demonstrating that m 6 A modification at either site of MAGI3 exon 10 functionally promotes interaction with experimentally validated m 6 A readers [10] [11] [12] . Following confirmation that m 6 A modification of MAGI3 exon 10 is functionally significant, we asked whether m 6 A modification in this exon differed between MDA-MB-231 and MCF10A cells by performing additional m 6 A RIP-qPCR experiments. We found that the relative abundance of m 6 A at both sites in the large internal exon of MAGI3 was significantly reduced in MDA-MB-231 compared to MCF10A cells ( Fig. 2D and E) .
pPA-truncated MAGI3 transcripts are largely depleted of m 6 A modifications. Having shown an overall reduction in large internal exon m 6 A modification for MAGI3 in pPA-activated cancer cells, we next endeavored to determine whether this overall depletion of m 6 A marks in the large internal exon is specific to pPA-truncated transcripts or whether it occurs indiscriminately between full-length and truncated isoforms. We hypothesized that if m 6 A levels do not contribute to the activation of pPA, then full-length and pPA-truncated MAGI3 transcripts will not differ significantly in methylation status. We modified the m 6 A RIP protocol used previously in order to test this null hypothesis by eliminating the chemical fragmentation step such that we could immunoprecipitate intact, poly(A)-purified RNA from MDA-MB-231 cells. In addition to the immunoprecipitated RNA, we also extracted mRNA from the unbound fraction. We subsequently performed 3′ RACE using MAGI3-specific forward primers and an oligo-d(T) reverse primer for each extracted fraction.
Strikingly, these experiments using m 6 A RIP-RACE revealed that pPA-truncated transcripts of MAGI3 were significantly enriched in the unmethylated fraction and depleted from the methylated fraction ( Fig. 3A and B) . In contrast, full-length MAGI3 transcripts were highly enriched in the methylated fraction, and only a minority was observed in the m 6 A-unbound fraction ( Fig. 3A and B) . As a control, we performed m 6 A RIP-RACE for GAPDH, which has no large internal exons and is not modified by m 6 A 7 . GAPDH transcripts were detected only in the unmethylated fraction, thus confirming the specificity of the m 6 A RIP-RACE (Fig. 3C ). These data demonstrate that hypomethylation of N 6 -adenosine in the large internal exon of MAGI3 is significantly associated with pPA-truncated, oncogenic MAGI3 transcripts. Taken together, our data to this point suggest that depletion of m 6 A modifications from the large internal exon of MAGI3 may somehow bias the favorability of using the downstream cryptic PAS in intron 10 ( Fig. 3D) . However, the generality of this proposed model remains uncertain and requires an understanding of whether other tumor suppressor genes (TSGs) also show evidence of pPA events following m 6 A-depleted large internal exons like MAGI3.
Evidence of pPA events following the large internal exons of additional tumor suppressor genes. To begin addressing these questions, we investigated whether other tumor suppressor genes (TSGs) also show evidence of pPA events following large internal exons like MAGI3. Using public mRNA isoform expression databases to survey fifty TSGs from the Cancer Gene Census 13 , we found that twenty of them harbor at least one large internal exon (defined as >500 nt) (Supplementary Table S1 ). Of these, seven TSGs (ATRX, BCOR, BRCA1, BRCA2, LATS1, MSH6 and RNF43) have previously annotated mRNA isoforms terminating in introns immediately following large internal exons ( Table 2) . As a caveat, we note that having identified truncations arising from pPA in these seven TSGs does not preclude the possibility that the other thirteen TSGs in the list might also undergo intronic pPA following large internal exons. These data suggest that pPA may act as a more common mechanism for truncating TSGs than previous appreciated.
Among the seven TSGs showing evidence of pPA, the truncated LATS1 isoform is particularly similar to MAGI3 pPA since previous studies have suggested that truncation products of LATS1 act to functionally oppose its tumor suppressive function. In the LATS1 gene, pPA occurs at a cryptic PAS in intron 4, following the 1.5-kb exon 4 (Fig. 4A ) 14 . This pPA-truncated transcript of LATS1 was identified in a candidate full-ORF cDNA library generated from a variety of cellular sources 14 , and has not been extensively studied since its initial annotation. Thus we performed 3′ RACE to validate its expression specifically in the "pPA-activated" MDA-MB-231 breast cancer cell line and non-transformed MCF10A cell line. Indeed by 3′ RACE, we observed an upregulation of the truncated LATS1 mRNA in MDA-MB-231 compared to MCF10A cells, apparently at the expense of full-length LATS1 levels (Fig. 4B) . By immunoblotting with an antibody raised against the N-terminal region of LATS1, we also found upregulation of LATS1 pPA in MDA-MB-231 compared to MCF10A cells (Fig. 4C) . Interestingly, the truncated LATS1 isoform (hereafter LATS1 pPA ) lacks the kinase domain necessary for suppressing oncogenic YAP activity but retains the YAP-interacting domain (Fig. 4D) . Overexpression of experimentally truncated LATS1 products of similar length to LATS1 pPA has been reported to dominantly interfere with LATS1-mediated regulation of the centrosome during mitosis, thus promoting mitotic delay and tetraploidy 15, 16 , and additionally bind to full-length LATS1 proteins in an inhibitory manner 17, 18 . Taken together, these data suggest that MDA-MB-231 breast cancer cells may have positively selected for the pPA-truncated product of LATS1 as a potentially oncogenic protein variant.
We also looked at BRCA1 as another example of the seven TSGs showing evidence of pPA. Following the 3.4-kb exon 10, the BRCA1-IRIS isoform is prematurely polyadenylated downstream of a close variant of the canonical PAS (AGUAAA) in intron 10 (Fig. 4E ) 19 . The expression of this truncated mRNA isoform has previously been extensively characterized by 3′ RACE, sequencing, RT-PCR and Northern blot analysis 19 . We immunoblotted MDA-MB-231 and MCF10A cell lysates with an antibody recognizing the N-terminal region of BRCA1 and observed that BRCA1-IRIS was present at higher levels in MDA-MB-231 versus MCF10A cells (Fig. 4F) . BRCA1-IRIS lacks key functional regions, such as the BRCT domains and protein-interacting regions (Fig. 4G) , and its expression has been previously reported to promote growth factor-independent cell proliferation, anchorage-independent colony formation, and subcutaneous tumor xenograft growth [19] [20] [21] [22] .
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A modification of LATS1 and BRCA1 large internal exons in MDA-MB-231 cells. To investigate whether the large internal exons of TSGs are also typically enriched in m 6 A modifications, we again examined transcriptome-wide m 6 A sequencing (m 6 A-Seq) datasets 7, 8 . Consistent with the pattern of m 6 A modification for the large internal exon of MAGI3, we found enrichment of m 6 A peaks in the large internal exons of LATS1 and BRCA1, as well as other TSGs (Supplementary Fig. S1 ). It is worth noting that the complexity of m 6 A modification patterns increased with greater internal exon lengths, and the largest internal exons frequently exhibited multiple, strong m 6 A peaks with additional, weaker m 6 A peaks throughout. After identifying putative large internal exon m 6 A sites by finding the consensus sequence RRACU in the strongest m 6 A peak regions of LATS1 and BRCA1, we performed m 6 A RIP-qPCR in MCF10A cells to validate the presence of m 6 A modifications. We validated m 6 A modifications in the two strongest peaks of LATS1 exon 4, with the downstream site exhibiting the highest modification level (Fig. 4H) . Meanwhile, for BRCA1 exon 10, we validated high levels of m 6 A modification in the most downstream site, but the upstream site showed much weaker enrichment by m 6 A RIP (Fig. 4I) .
We subsequently asked whether MDA-MB-231 cells differ in the levels of m 6 A modification in TSG large internal exons compared to MCF10A cells. We found that the relative abundance of m 6 A at the strongest, most downstream sites in the large internal exons of LATS1 and BRCA1 was significantly reduced in MDA-MB-231 cells ( Fig. 4J and K) , accompanied by less dramatic reductions at weaker upstream m 6 A sites ( Fig. 4L and M) . These data suggest that like MAGI3, reduced m 6 A levels in the large internal exons of LATS1 and BRCA1 also correlate with intronic pPA following large internal exons. 6 A levels and expression levels of m 6 A-modifying enzymes are comparable between MDA-MB-231 and MCF10A cells. Because we observed pPA-associated m 6 A hypomethylation in the large internal exon of MAGI3, as well as a general reductions in large internal exon m 6 A levels for BRCA1 and LATS1, we asked whether this phenomenon might be caused by an overall reduction in m 6 A levels transcriptome-wide in pPA-activated MDA-MB-231 cells compared to pPA-protected MCF10A cells. Thus we performed dot blot assays on purified poly(A) RNA from each cell line. These experiments showed that overall levels of m 6 A modification in the two cell lines are comparable (Supplementary Figure S2A and B) . We further examined whether the expression levels of genes encoding known m 6 A methyltransferase components (writers) or demethylase proteins (erasers) differ dramatically between MDA-MB-231 and MCF10A cells. We therefore assessed the expression levels of m 6 A writers METTL3, METTL14 and WTAP [23] [24] [25] [26] , as well as the expression levels of the m 6 A erasers FTO and ALKBH5 27, 28 , in MDA-MB-231 and MCF10A cells by qPCR (Supplementary Figures S2C-G) . Overall, we found that the expression levels of m 6 A-modifying enzymes were comparable between the two cell lines (Supplementary Figures S2C-G) , with only slight differences observed. Moreover, when m 6 A writers or erasers were considered together as functional groups, we did not observe collective trends in one cell line versus the other. For instance, while METTL3 levels were slightly higher in MDA-MB-231 cells, the other two m 6 A methyltransferase components, METTL14 and WTAP, were expressed at slightly lower levels compared to MCF10A cells (Supplementary Figures S2C-E) . Similarly, of the two m 6 A demethylases, FTO was expressed slightly more highly in MDA-MB-231 cells while ALKBH5 was expressed slightly more highly in MCF10A cells ( Supplementary  Figures S2F and G) . Taken together with the results from dot blot assays, the overall levels of m 6 A modification and the expression levels of m 6 A-modifying enyzmes do not necessarily distinguish the pPA-activated cell line, MDA-MB-231 from the non-transformed MCF10A cell line.
Overall m
Discussion
The molecular mechanism underlying cancer-associated, intronic premature polyadenylation of MAGI3 has remained unknown because no cis-acting genetic mutations were found in the gene, making it unclear how pPA of MAGI3 can specifically be activated in one intron but not in other introns that also harbor cryptic PAS 4 . In 
, large internal exon. The large internal exon of MAGI3 is by far the most highly m 6 A-modified exon in the gene, and we have shown by RIP-MS that the lack of m6A modification at the two m 6 A consensus sites in the exon diminishes the frequency of physical interactions between the mRNA and m 6 A-reading proteins. Furthermore, we have discovered that MAGI3 pPA transcripts are largely depleted of m 6 A modifications while full-length MAGI3 mRNA remains highly m 6 A-modified. Since its discovery, the functional impact of high m 6 A levels in the large internal exons of genes has remained unclear 7 . By identifying m 6 A as a cis-acting epitranscriptomic mark associated with MAGI3 mRNA shortening, we have drawn an unexpected connection between large internal exon m 6 A modifications in MAGI3 and the expression of cancer-associated, pPA-truncated MAGI3 transcripts. How cancer cells modulate m 6 A levels in the MAGI3 large internal exon to trigger pPA, and how this modulation of levels impacts pPA of MAGI3 from a mechanistic standpoint, are new questions that require further investigation. Regarding the former, several m 6 A-modifying enzymes have been recently identified, and alterations in some of these components, especially the m 6 A demethylase FTO, have been observed to correlate with human cancer risk 29, 30 . For the latter, a bias against pPA of MAGI3 rendered by m 6 A modification could be achieved via changes to the secondary structure of large internal exonic regions of the mRNA thus preventing downstream PAS recognition, or by binding of a m 6 A-binding protein that acts in concert with other protein factors to prevent intronic PAS usage, or a combination of both mechanisms. Indeed, similar mechanistic concepts regarding the structural aspects of genes and m 6 A-mediated post-transcriptional gene regulation have recently been put forth for consideration as a new paradigm for the coordination of gene expression 31, 32 . We have additionally analyzed publicly available mRNA expression data to report that intronic pPA-generated isoforms of other TSGs such as LATS1 and BRCA1 have been previously identified 14, 19 . These findings suggest that pPA may act as a more pervasive oncogenic mechanism for truncating TSGs with large internal exons than previously appreciated. Interestingly, we have also found that m 6 A levels in the large internal exons of LATS1 and BRCA1 are significantly lower in pPA-activated breast cancer cells relative to untransformed mammary cells. Taken together with the experiments showing that reduced m 6 A modification is associated with pPA-shortening of MAGI3, these data are conceptually consistent with those of a previous study showing that m 6 A density is inversely correlated with proximal PAS usage in terminal exons 9 . Thus, it is intriguing to speculate that m 6 A modification of large internal exons may play a role in regulating intronic pPA of TSGs beyond MAGI3, and additional studies of broader scope investigating the relationship between m 6 A levels in large internal exons and intronic pPA-mediated mRNA truncation for other TSGs are warranted.
Materials and Methods
Cell Lines and Tissue Culture. The cell lines used in this study were purchased from ATCC and grown as described previously 4 
.
Immunoblotting and Dot Blot Assays. Cell lysis, SDS-PAGE and immunoblotting were performed as described previously 4 . For dot blot assays, poly(A) RNA was purified from total RNA using DynaBeads mRNA Purification Kit (ThermoFisher). Poly(A) RNA was serially diluted to 180 ng/µl, 45 ng/µl, 11.25 ng/µl. Each dilution was dotted (2.5 µl) on a BrightStar-Plus positively charged nylon membrane (Invitrogen) in duplicate. The poly(A) RNA was crosslinked to the membrane in a Stratalinker 2400 Crosslinker twice (1,200 µl joules) and the membrane was washed for 5 minutes in wash buffer (Phosphate Buffered Saline, 0.02% Tween-20) before blocking for 1 hr (Phosphate Buffered Saline, 5% Milk, 0.02% Tween-20). The membrane was incubated overnight at 4 °C in polyclonal rabbit anti-m 6 A antibody (2 µg/ml) diluted in blocking buffer. Treatment with secondary antibody was performed according to standard immunoblotting procedures and m 6 A detection was visualized using enhanced chemiluminescence. Levels of m 6 A were quantified by measuring density of dots using Fiji ImageJ. Antibodies used are: β-actin (Abcam ab6276); BRCA1 (ThermoFisher MA1-23160); BRCA1(Santa Cruz Biotechnology sc-642); LATS1 Goat Santa Cruz Biotechnology sc-9388; m6A for RIP (New England Biolabs E1610); m and MDA-MB-231 cell pellets using the RNeasy Maxi Kit (Qiagen). Poly(A) RNA was purified from total RNA using the Oligotex Midi Kit (Qiagen). For m 6 A RIP-qPCR, RNA samples were chemically fragmented into ~100-nt length fragments by a 5 min incubation at 95 °C in NEBNext RNA fragmentation buffer from New England Biolabs (40 mM Tris-OAc, 100 mM KOAc, 30 mM Mg(OAc) 2 , pH 8.3). The fragmentation reaction was stopped with 50 mM EDTA, and one round of ethanol precipitation was performed to purify the fragmented poly(A) RNA. 3 µg fragmented poly(A) RNA was incubated for 1 hr at 4 °C with 1 µl EpiMark anti-m 6 A antibody (New England Biolabs) pre-bound to pre-washed Protein G magnetic beads in reaction buffer (150 mM NaCl, 10 mM Tris-HCl, pH 7.5, 0.1% NP-40). m 6 A-bound complexes were then washed twice in reaction buffer, followed by two washes in low salt reaction buffer (50 mM NaCl, 10 mM Tris-HCl, pH 7.5, 0.1% NP-40) and two washes in high salt reaction buffer (500 mM NaCl, 10 mM Tris-HCl, pH 7.5, 0.1% NP-40). Immunoprecipitated RNA was eluted in 30 µl Buffer RLT (Qiagen), then cleaned and concentrated using Dynabeads MyOne Silane (ThermoFisher) followed by ethanol washes. Bound RNA was eluted in 20 µl nuclease-free water and used for first-strand cDNA synthesis as described previously 4 . cDNA was also synthesized from total RNA, representing the input for m 6 A RIP. Samples were prepared for qPCR using isoform-specific or exon-specific primers. qPCR was performed in triplicate for each sample-target combination as described previously 4 . For determining gene expression, mRNA abundance was normalized to GAPDH. For m 6 A RIP samples, m 6 A levels of each target were normalized to overall expression levels of the target as determined by the same primer pair from total RNA. Targets spanning exons of the same gene but located far from the m 6 A sites within the large internal exons (distal mRNA segments) were also assayed. Primer sequences used for qPCR are: Forward Primer (F: 5′ to 3′), Reverse Primer (R: 5′ to 3′): BRCA1 exon 10 site 1F: TGAGTGGTTTTCCAGAAGTGA R: TCCCCATCATGTGAGTCATC; BRCA1 exon 10 site 2F: TCTCAGTTCAGAGGCAACGAR: TGGGTTTTGTAAAAGTCCATGTT; BRCA1-distal (exons 2-3) F: CGCGTTGAAGAAGTACAAAATG R:CAGGTTCCTTGATCAACTCCA; LATS1 exon 4 site 1F: GACCTGGAATGCAGAATGGT R: GCAGGGACAACATTTTGGTG; LATS1 exon 4 site 2F: GCCT GTGAAAAGTATGCGTGT R: GGCTGTGGTATCCAAGAAGG; LATS1-distal (exons 2-3) F: ACTTGC AAGCTGCTGGATTT R: TGTTGTTAGTTTTCTGAAGAGCTTG; MAGI3 exon 10 site 1F: TGGACAGTC ATTAACCAAGGGA R: GCTCCAGAACCATTGCTCCT; MAGI3 exon 10 site2 F: CATCGTCAGGCAGCTCCC R: TGCAAACCCAAACCCTTTAGG; MAGI3-distal (exons 1-2) F: CGTCTCAAGACTGTGAAACCA R: GACTTAGGTAATGCCGCAATC; GAPDH F: CCATGGGGAAGGTGAAGGTC R: TAAAAGCAG CCCTGGTGACC; ALKBH5 F: TTCAAGCCTATTCGGGTGTC R: GGCCGTATGCAGTGAGTGAT; FTO F: AATCTGGTGGACAGGTCAGC R: TGCCTTCGAGATGAGAGTCA; METTL3 F: CCCACTGA TGCTGTGTCCAT R: CTGCAGGAGGCTTTCTACCC; METTL14 F: TCCAAAGGCTGTCTTTCAGAGA R: GAAGTCCCCGTCTGTGCTAC; WTAP F: ACAAGCTTTGGAGGGCAAGT R: GATGTTTT CCCTGCGTGCAG.
For m 6 A RIP-RACE, RNA samples were not subjected to the fragmentation step and used directly for m 6 A-RIP. 3 µg unfragmented poly(A) RNA was incubated for 1 hr at 4 °C with 1 µl EpiMark anti-m 6 A antibody (New England Biolabs) pre-bound to pre-washed Protein G magnetic beads in reaction buffer (150 mM NaCl, 10 mM Tris-HCl, pH 7. Statistical Analysis. Data were analyzed and compared between groups using two-tailed Student's t-tests. A p < 0.05 was considered statistically significant.
